SHANGHAI, China, June 22, 2026
CureGene Pharmaceutical has announced the successful dosing of the first participant in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary next-generation antiplatelet therapy designed to address major unmet needs in the treatment of cardiovascular and cerebrovascular diseases. The milestone represents a critical advancement toward a future New Drug Application (NDA) submission in the United States and strengthens CureGene’s strategy to position Evategrel as a potential best-in-class antiplatelet drug for global markets. As cardiovascular diseases remain the leading cause of death worldwide, the initiation of this registrational study highlights growing efforts to develop faster, safer, and more effective therapies capable of preventing life-threatening thrombotic events such as heart attacks and strokes.
Novel Mechanism Targets Long-Standing Antiplatelet Challenges
Evategrel is the leading candidate emerging from CureGene’s proprietary A-proX™ Prodrug Platform and is recognized as the world’s first P2Y12 receptor inhibitor available in both intravenous and oral formulations. Unlike conventional therapies such as clopidogrel, which rely on CYP450 enzyme metabolism, Evategrel utilizes an innovative thiol-hydrolyzing prodrug technology that enables activation through hydrolases naturally present throughout human tissues. This breakthrough mechanism completely bypasses CYP450-dependent metabolic pathways and has the potential to eliminate major limitations associated with current antiplatelet therapies.
The technology is designed to overcome clopidogrel resistance, a challenge affecting a significant proportion of patients, particularly among East Asian populations, while also reducing inter-patient variability, minimizing drug-drug interactions, and delivering more predictable therapeutic outcomes. By addressing these long-standing treatment barriers, Evategrel may represent a transformative advancement in the field of cardiovascular medicine.
Pivotal U.S. Trial Aims to Support Global Regulatory Filings
Advertisement
The ongoing U.S. registrational study is designed to evaluate the efficacy and safety of both the injectable and oral formulations of Evategrel compared with clopidogrel across multiple high-risk patient populations. The trial includes individuals with acute coronary syndrome (ACS), recent myocardial infarction, ischemic stroke, and peripheral arterial disease. Data generated from this study will serve as core evidence supporting future regulatory submissions in the United States and other global markets. Simultaneously, CureGene continues to advance the program in China after receiving approval from the Center for Drug Evaluation (CDE), with a Phase II ischemic stroke trial expected to begin soon. The synchronized development strategy in both China and the United States is intended to accelerate worldwide commercialization and facilitate simultaneous regulatory filings, potentially positioning Evategrel for approval as early as 2027.
Clinical Data Highlights Rapid Action and Strong Safety Profile
Previous clinical studies have demonstrated several highly promising advantages for Evategrel. The therapy has shown an ultra-rapid onset of action, reaching peak antiplatelet activity in less than 15 minutes for the intravenous formulation and under 30 minutes for the oral formulation, making it particularly valuable in emergency cardiovascular and stroke settings where immediate intervention is critical. Additionally, Evategrel achieves potent antiplatelet effects at a dose approximately 1% of the standard clopidogrel dose, potentially reducing medication burden while maintaining efficacy. Clinical evaluations have also indicated a favorable safety profile characterized by low bleeding risk and minimal interaction with other medications, making the therapy particularly attractive for elderly patients and individuals with multiple underlying conditions requiring complex treatment regimens.
According to CureGene Founder and CEO Dr. Gongxin He, the successful initiation of the U.S. pivotal trial marks a defining moment in the company’s mission to develop globally competitive innovative medicines. As the program advances through late-stage clinical development, Evategrel could emerge as a next-generation therapy capable of reshaping antiplatelet treatment standards and improving outcomes for millions of patients affected by cardiovascular and cerebrovascular diseases worldwide.
Source: CureGene Pharmaceutical press release
